<DOC>
	<DOCNO>NCT00107380</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody , iodine I 131 tositumomab , find cancer cell carry cancer-killing substance without harm normal cell . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy , cyclophosphamide , doxorubicin , vincristine , prednisone , work different way stop growth cancer cell , either kill cell stop divide . Giving radiolabeled monoclonal antibody together rituximab combination chemotherapy may kill cancer cell . PURPOSE : This phase II trial study well give iodine I 131 tositumomab together rituximab combination chemotherapy work treat old patient stage II , stage III , stage IV B-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>S0433 Iodine I 131 Tositumomab , Rituximab , Combination Chemotherapy Treating Older Patients With Stage II , Stage III , Stage IV Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine 2-year progression-free survival old patient previously untreated bulky stage II stage III IV diffuse large B-cell non-Hodgkin 's lymphoma treat iodine I 131 tositumomab combination rituximab , cyclophosphamide , doxorubicin , vincristine , prednisone . - Determine response rate ( partial response , complete unconfirmed response , complete response ) patient treat regimen . - Determine 2-year progression-free survival response rate ( partial response , complete unconfirmed response , complete response ) B-cell lymphoma 2 ( BCL-2 ) positive patient treated regimen . OUTLINE : This multicenter study . - Rituximab chemotherapy : Patients receive R-CHOP comprise rituximab IV 6 hour ; cyclophosphamide IV 15-45 minute ; doxorubicin IV 5-20 minute ; vincristine IV 5-15 minute day 1 oral prednisone day 1-5 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients undergo restaging evaluation . Patients without progressive disease receive CHOP chemotherapy comprise cyclophosphamide , doxorubicin , vincristine , prednisone outline . Treatment CHOP chemotherapy repeat every 21 day 2 course . - Radiolabeled monoclonal antibody therapy : Approximately 4-8 week completion chemotherapy , patient receive tositumomab IV 1 hour follow dosimetric dose iodine I 131 tositumomab IV 20 minute . Patients undergo gamma scan 1-week period order determine correct treatment dose iodine I 131 tositumomab . No 2 week administration dosimetric dose , patient receive tositumomab IV 1 hour follow treatment dose iodine I 131 tositumomab IV 20 minute . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 80 patient accrue study within 15 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis diffuse large Bcell nonHodgkin 's lymphoma , meet 1 follow stage criterion : Bulky stage II disease Stage III disease Stage IV disease Confirmed cluster differentiation antigen 20 ( CD20 ) antigenpositive disease Bidimensionally measurable disease Less 20,000/mcL circulate lymphoid cell white blood cell ( WBC ) differential count Adequate section AND paraffin block OR ≥ 10 unstained section original diagnostic specimen available Needle aspiration cytology consider adequate No clinical evidence central nervous system ( CNS ) involvement lymphoma No prior diagnosis indolent lymphoma No histologic transformation PATIENT CHARACTERISTICS : Performance status Zubrod 02 Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Not specify Renal Not specify Cardiovascular Ejection fraction ≥ 45 % multiple gated acquisition scan ( MUGA ) OR No significant abnormality echocardiogram Pulmonary No requirement continuous supplemental oxygen Other Fertile patient must use effective contraception 6 month completion study treatment No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , stage I II cancer complete remission , carcinoma situ cervix No known HIV positivity PRIOR CONCURRENT THERAPY : Biologic therapy No prior antibody therapy lymphoma Chemotherapy No prior chemotherapy lymphoma Endocrine therapy Not specify Radiotherapy No prior radiotherapy lymphoma Surgery No prior solid organ transplantation Other Concurrent enrollment protocol SWOG8947 ( lymphoma serum repository ) protocol SWOG8819 ( lymphoma tissue repository ) encourage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
</DOC>